- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03287076
Trial of EXenatide in Acute Ischaemic Stroke (TEXAIS)
A Multicentre, Randomised Controlled Trial of Exenatide Versus Standard Care in Acute Ischemic Stroke (TEXAIS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Overview: Elevated blood glucose levels are common in many acute diseases, resulting in worse clinical outcomes. Hyperglycaemia in acute ischaemic stroke (post-stroke hyperglycaemia [PSH]) occurs in up to 50% patients, reduces the efficacy of stroke thrombolysis with increased risk of haemorrhage, increases infarct size, and results in worse clinical outcomes and death. Insulin-based therapies have not proved beneficial in treating PSH: they are difficult to implement and maintain, cause frequent hypoglycaemia, may cause increased infarct size, and do not reduce mortality or improve clinical outcomes. An alternative, simple to use, treatment for PSH may therefore have a significant impact not only for acute stroke care, but in other acute diseases.
Pilot data: Exenatide is a commonly used diabetes drug (a synthetic glucagon- like peptide-1 receptor agonist) that increases insulin secretion. Importantly, this action is glucose dependent - as blood glucose levels decrease, its stimulatory effect on insulin secretion subsides, with a very low risk of hypoglycaemia. A small randomised pilot study of 17 consecutive, unselected patients (ie. regardless of their admission glucose level) with acute ischaemic stroke compared subcutaneous exenatide 5μg for 5 days with routine standard of care. Overall, blood glucose levels remained consistently lower (and less variable) in the exenatide group, and most noticeably in those stroke patients with known diabetes. Exenatide was safe and well tolerated by all patients, with no symptomatic hypoglycaemia.
Trial design: TEXAIS is a 3 year Phase 2, multi centre, prospective, randomised, open label, blinded end-point (PROBE) trial comparing Exenatide to Standard of Care. The sample size is 528 patients (264 in each arm).
Intervention: Treatment arm will receive Exenatide (Byetta) 5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset. Stroke onset time for wake-up strokes is taken as mid-point between going to bed, and waking up. Antiemetic therapy (metoclopramide or ondansetron) will be commenced with the first dose of Exenatide. In patients receiving tPA, Exenatide will be given alongside, or as soon as possible, following tPA administration (within 60 minutes). Diabetic patients already on oral agents and/or insulin may continue these (as per standard practice) in addition to Exenatide. Continuous glucose monitors (CGMs) will track the intra-day dynamic variability of glucose in acute stroke.
Translation: TEXAIS is a simple, practical, study that can enrol all patients with ischaemic stroke, regardless of admission blood glucose level, regardless of stroke severity, with no target glucose level, and with low risk of hypoglycaemia.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- St Vincent's Hospital Sydney
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital
-
-
Queensland
-
Birtinya, Queensland, Australia, 4575
- Sunshine Coast University Hospital
-
Herston, Queensland, Australia, 4029
- Royal Brisbane and Women's Hospital
-
Woolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
Tasmania
-
Launceston, Tasmania, Australia, 7250
- Launceston General Hospital
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Box Hill Hospital
-
Fitzroy, Victoria, Australia, 3065
- St Vincent's Hospital Melbourne
-
Heidelberg, Victoria, Australia, 3084
- Austin Hospital
-
Melbourne, Victoria, Australia, 3004
- Alfred Hospital
-
Parkville, Victoria, Australia, 3050
- Royal Melbourne Hospital
-
-
Western Australia
-
Midland, Western Australia, Australia, 6056
- St John of God Midland Public & Private Hospital
-
Murdoch, Western Australia, Australia, 6150
- Fiona Stanley Hospital
-
-
-
-
-
Helsinki, Finland, 00290
- Helsinki University Hospital
-
-
-
-
-
Christchurch, New Zealand, 8140
- CDHB Christchurch Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females 18 years or older
- Acute Ischaemic Stroke - CT brain exclusion of haemorrhagic stroke
- Blood glucose level on admission ≥ 4mmol/L
- First trial treatment possible within 9 hours of stroke onset
- Pre-morbid /mRS score of 0-2
Exclusion Criteria:
- Haemorrhagic stroke
- Poor clinical prognosis /palliation (considered unlikely to survive beyond 14 days post stroke).
- Any known allergy or hypersensitivity to Exenatide
- Females who are pregnant (known or suspected) or currently breastfeeding
- Any past history of pancreatitis or evidence of active pancreatitis
- History of active severe gastrointestinal disease (including but not limited to gastroparesis and dumping syndrome)
- Current chronic kidney disease stage 4 or 5 (creatinine clearance <30ml/min)
- Current participation in another interventional clinical trial
- Inability to provide consent (participant or person responsible as local laws apply)
- Current use of Exenatide (Byetta®), or other GLP-1 agonist diabetes medication
- Patients considered unlikely to be able to be followed up at 3 months (including but not limited to geographical location of patient at 3 months)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Active
Patients will receive exenatide injections
|
5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
Other Names:
|
NO_INTERVENTION: Standard Care
Standard care for stroke as per hospital protocol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
improved neurological outcome
Time Frame: 7 days
|
Treatment with short acting Exenatide (Byetta) in patients with acute ischaemic stroke is hypothesised to improve neurological outcome as measured by ≥8 point improvement in the National Institutes of Health Stroke Scale (NIHSS) stroke disability score (or NIHSS 0-1) at 7 days
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
post stroke hyperglycaemia
Time Frame: 90 days
|
reduce the occurrence of post stroke hyperglycaemia (>7mmol/l).
|
90 days
|
Modified Rankin Scale
Time Frame: 90 days
|
improve Modified Rankin Scale (mRS) at 90 days
|
90 days
|
NIHSS
Time Frame: 90 days
|
improve NIHSS at 90 days
|
90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christopher Bladin, The Florey Institute of Neuroscience & Mental Health Melbourne Brain Centre
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Brain Ischemia
- Infarction
- Brain Infarction
- Stroke
- Ischemic Stroke
- Ischemia
- Cerebral Infarction
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Obesity Agents
- Incretins
- Exenatide
Other Study ID Numbers
- NTA1127
- 2018-004325-88 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Ischemic Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAcute Ischemic Stroke (AIS)United States
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalCompletedIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
-
Memorial Sloan Kettering Cancer CenterWeill Medical College of Cornell University; New York Presbyterian HospitalCompletedCancer Patients First-ever Acute Ischemic StrokeUnited States
Clinical Trials on Exenatide Injection
-
PegBio Co., Ltd.Completed
-
University of Maryland, BaltimoreTerminated
-
The First Affiliated Hospital of Xiamen UniversityCompletedDiabetes Mellitus, Type 2China
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusUnited States
-
TheracosCompletedType2 Diabetes MellitusUnited States
-
Xiangya Hospital of Central South UniversityRecruiting
-
Intarcia TherapeuticsCompletedType 2 DiabetesUnited States
-
AstraZenecaCompletedType 2 Diabetes MellitusCanada, United States
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusKorea, Republic of, China, Japan, Taiwan, India